Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis

Table 2 Univariate analysis with Kaplan–Meier and Cox proportional hazards model of the clinical characteristics affecting delayed metastasis in 2nd cohort

	Number	MFS (mean ± SD, months)	Log-Rank	Univariate HR (±95% CI)
Age (years)			0.034
≤50	270	149.53 ± 2.57
> 50	263	135.87 ± 3.18		1.796 (1.036–3.113)
Tumor size (cm)			0.043
≤2	296	148.20 ± 2.63
> 2	237	142.36 ± 3.40		1.737 (1.009–2.992)
Lymph node metastasis			0.002
No	331	149.38 ± 2.46
Yes	202	139.48 ± 3.78		2.334 (1.351–4.031)
Histologic grade			0.395
1 and 2	354	141.77 ± 2.47
3	179	144.54 ± 3.58
Estrogen receptor			0.088
Negative	165	151.02 ± 3.52
Positive	368	143.35 ± 2.58
Progesterone receptor			0.094
Negative	220	149.99 ± 3.15
Positive	313	138.71 ± 2.67
HER-2			0.005
Negative	417	148.04 ± 2.37
Positive	103	118.6 ± 4.10		2.208 (1.247–3.911)
Pre NLR (cut-off 1.82)			0.020
Low	269	150.01 ± 2.55
High	264	141.11 ± 3.37		1.920 (1.095–3.367)
Pre PLR (cut-off 204.27)			0.007
Low	459	148.10 ± 2.10
High	74	133.19 ± 6.301		2.238 (1.230–4.073)
2nd NLR (cut-off 1.76)			0.001
Low	365	149.22 ± 2.32
High	168	137.48 ± 4.31		2.434 (1.420–4.172)
2nd PLR (cut-off 112.67)			< 0.001
Low	283	151.85 ± 2.31
High	250	138.70 ± 3.58		2.759 (1.535–4.960)

ISSN: 1471-2407